Does EU Approval Of ENFLONSIA Reshape The Bull Case For Merck's Pipeline Story (MRK)? [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
tract disease in newborns and infants during their first RSV season across the EU, Iceland, Liechtenstein and Norway. This decision adds another globally approved product backed by late-stage CLEVER and SMART trial data to Merck's growing portfolio of infant and pediatric preventive therapies. We'll now examine how adding an EU-wide RSV prevention option like ENFLONSIA could influence Merck's pipeline-led investment narrative. This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality Merck Investment Narrative Recap To own Merck, you need to believe its broad pipeline and new launches can progressively offset concentration in KEYTRUDA and pockets of vaccine softness, while regulatory and pricing risks stay manageable. The ENFLONSIA approval in Europe strengthens the infant prevention franchise, but it does not change the near term focus on oncology milestones and how effectively Merck backfills eventual KEYTRUDA exclusiv
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder CancerBusiness Wire
- Roche's DAC investment; Big Pharma's lavish CEO bumps [Yahoo! Finance]Yahoo! Finance
- Better Pharma Dividend Stock: Novartis vs. Merck [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Better Pharma Dividend Stock: Novartis vs. Merck [Yahoo! Finance]Yahoo! Finance
- UBS Raises Merck (MRK) Price Forecast as Part of Sector Preview [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 4/8/26 - Form ARS
- 4/8/26 - Form DEFA14A
- 4/8/26 - Form DEF
- MRK's page on the SEC website